Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TIM3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TIM3 (HAVCR2) ECD-Fc Fusion Protein (also available as Mutant Protein). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View TIM3 Products |
| Gene Delivery | TIM3 Full-Length ORF Lentivirus. For stable cell line construction in HEK293 or CHO cells. Theoretical MW validation. | View TIM3 Products |
| Benchmark Ab | Anti-TIM3 (Sequence of Sabatolimab / Cobolimab). Recombinant positive control for blocking assays. | View TIM3 Products |
| Validator | TIM3 siRNA Set (3 unique sequences). For knockdown specificity verification. | View TIM3 Products |
| Related Target: PD-1 | PDCD1 / PD-1. Synergistic checkpoint pathway; essential for combination therapy development. | View PDCD1 Products |
| Related Target: CEACAM1 | CEACAM1 / CD66a. Heterophilic ligand for TIM3; critical for cis/trans interaction studies. | View CEACAM1 Products |
| Related Target: LAG3 | LAG3 / CD223. Co-inhibitory receptor; tri-checkpoint combination therapy candidate. | View LAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval for toxicology | Human/Cyno/Mouse ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Ligand competition (Galectin-9 & CEACAM1) | High-affinity ECD-Fc fusion preserves native conformation for competitive SPR/BLI assays. |
| Internalization potential (ADC development) | Lentivirus-premade stable cell lines for flow cytometry-based uptake quantification. |
| False positive screening | Validated siRNA included for specificity checks; Sequence-verified ORF controls. |
| Lack of positive controls | Clinical Benchmark Antibodies (biosimilars) included for assay baseline establishment. |
Live TIM3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TIM3-targeted therapeutics has pivoted from monotherapy ambitions to combination strategies. Following setbacks in solid tumor indications, current development prioritizes myeloid malignancies (MDS/AML) where TIM3+ leukemic stem cells represent a distinct therapeutic vulnerability. Major players including Novartis (Sabatolimab), Roche (Cobolimab, RO7121660), Eli Lilly, and GSK are advancing Phase II/III programs. The next wave focuses on bispecific formats (PD-1/TIM3) to overcome T-cell exhaustion, and tailored ligand-blocking profiles (e.g., Galectin-9 vs. CEACAM1) for differentiation. As first-generation therapies reach advanced stages, differentiation will depend on epitope selection and Fc-engineering for enhanced myeloid cell depletion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Fc-enhanced) | Novartis, Roche, Eli Lilly, GSK | MDS, AML, Solid Tumors | Ligand competition assay (need pure TIM3 ECD-Fc vs. Galectin-9/CEACAM1) |
| Bispecific (PD-1/TIM3) | Roche (RO7121660), Eli Lilly, Macrogenics | Advanced Solid Tumors, Refractory Solid Tumors | Heterodimer validation (need cross-reactive PD-1 and TIM3 antigens) |
| ADC (Investigational) | Emerging Biotechs, Early Stage Biotech | TIM3+ Solid Tumors, Hematological Malignancies | Internalization assay (need full-length TIM3 lentivirus cell line) |
Molecular Differentiation & Assay Strategy
To develop best-in-class TIM3 inhibitors, three key dimensions require rigorous assay support:
-
Affinity & Epitope Selection: TIM3 interacts with multiple ligands (Galectin-9, CEACAM1, HMGB1, PtdSer). Candidate antibodies must selectively block disease-relevant interactions while sparing beneficial immune surveillance. Assay recommendations: Competitive SPR/BLI, ligand-blocking ELISA, epitope binning. TarMart provides high-purity ECD-Fc with native glycosylation (critical for Galectin-9 binding).
-
Fc-Effector Function & Safety: Most clinical antibodies use IgG4 or Fc-silent IgG1 to avoid ADCC/CDC killing of TIM3+ effector T cells. However, for myeloid-depleting strategies, Fc-enhanced antibodies are emerging. Assay requirements: ADCC reporter assays using TIM3-overexpressing cell lines (generated via TarMart lentivirus).
-
Cross-Species Reactivity: Non-human primate (NHP) toxicity studies require antibodies that cross-react with cynomolgus TIM3 (sequence identity ~90%). TarMart offers matched human/cyno/mouse ortholog proteins (>95% purity, mass-spec verified) for parallel binding validation.
Additionally, natural mutations (e.g., in SPTCL: VAR_082211, VAR_082212, VAR_082213) affect protein folding and subcellular localization, providing insights for antibody epitope design. The Ig-like V-type domain (UniProt Q8TDQ0) is the primary target for ligand-blocking antibodies.
Related Target Cross-sell
Based on pathway synergy and clinical combination trends:
- PD-1/PD-L1: Most common combination partner for TIM3.
- LAG-3: Parallel exhaustion receptor for triple therapy.
- CEACAM1: Heterophilic ligand for TIM3; essential for cis/trans interaction studies.
- Galectin-9: Key ligand for apoptosis induction assays.